Skip to main content
Clinical Trials/NCT01653769
NCT01653769
Completed
N/A

CoSeal for Hemostasis of Aortic Anastomoses: A Propensity-Matched Cohort Study

Michael Reardon, MD1 site in 1 country150 target enrollmentJune 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Surgical Bleeding
Sponsor
Michael Reardon, MD
Enrollment
150
Locations
1
Primary Endpoint
reduction in intra- and post-operative bleeding for procedures using CoSeal for hemostasis
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Surgery on the aorta can be associated with significant blood loss. Most commonly this is due to bleeding at the site of aortic anastomosis. Surgical bleeding is associated with significant morbidity.

One way to prevent bleeding is to use a special glue (sealant) after performing large connections on the aorta. The goal of this study is to compare the different methods surgeons use to stop/prevent bleeding.

The study team will collect medical information about patients before, during, and after surgery on their aortas, including the methods used to prevent bleeding. This information may help doctors improve the way that they care for these patients.

Detailed Description

Bleeding is a major complication of cardiac surgery, and a significant cause of morbidity and mortality \[1-4\]. Hemostasis can be challenging during complex cardiac surgery, particularly due to friability of the tissue, coagulopathy, poor visualization of the surgical field, and limited accessibility to bleeding sites \[5\]. Failure to achieve and maintain hemostasis and reinforce fragile tissue may result in additional bleeding, which can further reduce visualization, increase operative blood loss, lengthen surgery, increase the use of blood products, and contribute to postoperative complications and reoperation \[1-4\]. Postoperative bleeding is a significant concern in cardio-thoracic surgery. Bleeding, either intraoperative or postoperative, has been associated with extended in-hospital length of stay, reoperations, severe morbidity and death \[12\]. In addition to surgical technique, a variety of therapeutic agents are available to assist in hemostasis. Surgical sealants are used to prevent suture line bleeding when ligation or conventional methods are ineffective or impractical \[13\]. CoSeal® Surgical Sealant (CoSeal®, Baxter, Westlake Village, CA) is a synthetic polyethylene glycol (PEG) polymer \[11, 13\]. The polymers cross-link with proteins in the tissue and begin to gel in approximately 5 seconds and set within 60 seconds, forming a strong, flexible, clear, degradable hydrogel that adheres to both tissue and synthetic graft surfaces \[11, 13-14\]. A secure seal is maintained through covalent tissue bonds even under high pressures in vessels, such as the aorta \[15\]. The gel is completely resorbed within 30 days \[14\].

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
December 2015
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Michael Reardon, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Michael Reardon, MD

Sponsor-Investigator/Principal Investigator

The Methodist Hospital Research Institute

Eligibility Criteria

Inclusion Criteria

  • The study will include all patients undergoing cardio-thoracic surgery requiring a large aortic anastomosis.

Exclusion Criteria

  • Patients with severe preoperative coagulopathy, connective tissue disorders and disseminated intravascular coagulopathy (DIC) will be excluded.

Outcomes

Primary Outcomes

reduction in intra- and post-operative bleeding for procedures using CoSeal for hemostasis

Time Frame: from day of surgery to 15-30 days after discharge

estimated blood loss/chest drain output; blood product requirement during surgery; re-operation for bleeding

Secondary Outcomes

  • decrease length of stay(participants will be followed for the duration of hospital stay, an expected average of 2 weeks)

Study Sites (1)

Loading locations...

Similar Trials